Abstract: The present disclosure provides bispecific anti-VEGF×PD-L1 antibody or antigen-binding portion thereof, methods of producing the bispecific antibody or antigen-binding portion thereof, methods of treating diseases or conditions using the bispecific antibody or antigen-binding portion thereof.

Abstract: Provided D3-binding molecules, including anti-D3antibodies, and their uses.

Abstract: The present invention provides novel anti-PD-1 antibodies that specifically bind to cell surface PD-1. Also provided are the nucleic acid molecules encoding the anti-PD-1 antibodies, expression vectors and host cells used for the expression of the anti-PD-1 antibodies. The invention further provides the methods for producing the anti-PD-1 antibodies and the use thereof.

Abstract: The present invention provides novel anti-PD-1 antibodies that specifically bind to cell surface PD-1. Also provided are the nucleic acid molecules encoding the anti-PD-1 antibodies, expression vectors and host cells used for the expression of the anti-PD-1 antibodies. The invention further provides the methods for producing the anti-PD-1 antibodies and the use thereof.

Abstract: This disclosure provides multispecific and multivalent antigen binding proteins. In one aspect, the disclosure provides a multispecific antigen binding protein, comprising a first antigen binding site comprising a first VHH that specifically binds to a first epitope; and a second antigen binding site that specifically binds to a second epitope.

Abstract: The present disclosure provides anti-EGFR antibody polypeptides, polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the uses thereof.

Abstract: Provided are bispecific anti-VEGF×PD-L1 antibody or antigen-binding portion thereof, methods of producing the bispecific antibody or antigen-binding portion thereof, and methods of treating diseases or conditions using the bispecific antibody or antigen-binding portion thereof.

Abstract: The present disclosure provides anti-CTLA-4 antibody polypeptides, polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the uses thereof.

Abstract: The present disclosure provides anti-LAG-3 heavy-chain antibody or the antigen-binding domain thereof, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the uses thereof.

Abstract: The present disclosure provides a fusion protein comprising at least a portion of TGF?RII and anti-PD-L1 antibody or antigen-binding portion thereof, methods of producing the fusion protein, methods of treating diseases or conditions using the fusion protein, and uses thereof.

Abstract: Provided is a polypeptide, comprising, from N-terminus to C-terminus, a) at least a variable region of a heavy chain of a heavy-chain antibody (VHH domain) that binds protein Programmed Death Ligand 1 (PD-L1), operably linked to IgG Fc binding domain; and b) human TGF?RII, or a fragment thereof capable of binding TGF?. An antibody comprises the said polypeptide, the amino acid sequences of the said antibody, cloning or expression vectors, cells and methods for expressing or isolating the antibodies are further provided. Therapeutic compositions comprising the said antibodies, and the methods for treating cancers and other diseases with the bispecific antibodies are also provided.

Abstract: Provided are anti-PD-L1 antibodies. It also provides the nucleic acid molecules encoding the anti-PD-L1 antibodies, expression vectors and host cells used for the expression of the anti-PD-L1 antibodies. It also provides the methods for producing the anti-PD-L1 antibodies and the use thereof.

Abstract: Provided are bispecific antibodies against PD-L1 and LAG-3, the nucleic acid molecules encoding the antibodies, expression vectors and host cells used for the expression of the antibodies. Provided are the methods for validating the function of antibodies in vivo and in vitro. The antibody is a potent agent for the treatment of cancers via modulating immune functions.

Abstract: Bispecific antibodies comprising a first targeting moiety which specifically binds to PD-1 and a second targeting moiety which specifically binds to LAG-3, wherein the first targeting moiety comprises a first VHH domain and the second targeting moiety comprises a second VHH domain. Amino acid sequences of the antibodies of the invention, cloning or expression vectors, host cells and methods for expressing or isolating the antibodies. Therapeutic compositions comprising the antibodies of the invention are also provided and methods for treating cancers and other diseases with the bispecific antibodies.

Abstract: The present disclosure provides anti-LAG-3 heavy-chain antibody or the antigen-binding domain thereof, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the uses thereof.

Abstract: The present disclosure provides a bispecific anti-CD3×CD20 polypeptide complex that contains a first antigen-binding moiety of the polypeptide complex and a second antigen-binding moiety, methods of producing the bispecific anti-CD3×CD20 polypeptide complex, methods of treating disease or disorder using the bispecific anti-CD3×CD20 polypeptide complex, polynucleotides encoding the bispecific anti-CD3×CD20 polypeptide complex, vectors and host cells containing said polynucleotides, and compositions and pharmaceutical compositions comprising the bispecific anti-CD3×CD20 polypeptide complex.

Abstract: Disclosed are a photography control method, device, non-transitory storage medium and system of an intelligent photography system. The photography control method of the intelligent photography system includes: acquiring a target positioning image shot by the search camera and a viewfinder screen image shot by the shooting camera, and transmitting the target positioning image and the viewfinder screen image to a remote terminal for the remote terminal to generate a search camera angle adjustment instruction according to the target positioning image and the viewfinder screen image; receiving the search camera angle adjustment instruction sent by the remote terminal; and acquiring an angle adjustment parameter according to the search camera angle adjustment instruction to control the search camera to adjust an angle.